SkinBioTherapeutics (SBTX) Competitors GBX 17 +0.25 (+1.49%) As of 08/1/2025 12:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock SBTX vs. CIR, BVXP, 4BB, TILS, VSN, SCLP, OBI, MPH, HVO, and ORPHShould you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Ondine Biomedical (OBI), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry. SkinBioTherapeutics vs. Its Competitors Circassia Group Bioventix 4basebio Tiziana Life Sciences Verseon Scancell Ondine Biomedical Mereo BioPharma Group plc (MPH.L) hVIVO Open Orphan SkinBioTherapeutics (LON:SBTX) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do institutionals & insiders believe in SBTX or CIR? 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 20.4% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor SBTX or CIR? In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score. Company Overall Sentiment SkinBioTherapeutics Neutral Circassia Group Neutral Which has stronger valuation and earnings, SBTX or CIR? Circassia Group has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkinBioTherapeutics£1.56M24.88-£3.71M-£1.63-10.46Circassia Group£27.90M0.00N/A£0.01N/A Is SBTX or CIR more profitable? Circassia Group has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -237.95%. Circassia Group's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SkinBioTherapeutics-237.95% -115.86% -61.18% Circassia Group N/A N/A N/A SummaryCircassia Group beats SkinBioTherapeutics on 6 of the 8 factors compared between the two stocks. Get SkinBioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£38.83M£134.75M£5.52B£3.03BDividend YieldN/A3.74%4.74%5.02%P/E Ratio-10.463.8028.93176.75Price / Sales24.884,246.60440.51264,362.45Price / Cash9.0013.1935.0727.97Price / Book10.1339.388.254.53Net Income-£3.71M-£90.99M£3.25B£5.90B7 Day Performance4.05%-2.02%-3.75%12.58%1 Month Performance3.03%3.61%2.99%4.67%1 Year Performance23.64%186.14%25.35%72.88% SkinBioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSkinBioTherapeuticsN/AGBX 17+1.5%N/A+21.7%£38.83M£1.56M-10.4611CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,720-1.1%N/A-40.2%£142.43M£13.65M17.59124BB4basebio1.9772 of 5 starsGBX 941-3.0%GBX 1,600+70.0%-29.4%£120.54M£311K-1,206.41101News CoverageGap DownHigh Trading VolumeTILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60M-3.5911VSNVerseonN/AN/AN/AN/A£112.24MN/A-5.17N/AGap UpSCLPScancellN/AGBX 9.65-1.0%N/A-35.2%£99.95MN/A-14.8051News CoverageOBIOndine BiomedicalN/AC$13.28-1.6%N/A+53.5%C$95.48MC$48.60K-4.00N/APositive NewsMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownHVOhVIVO2.5066 of 5 starsGBX 10+2.6%GBX 35+250.0%-66.3%£70.76M£68.74M4.12N/ANews CoverageAnalyst ForecastGap UpORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179News Coverage Related Companies and Tools Related Companies Circassia Group Alternatives Bioventix Alternatives 4basebio Alternatives Tiziana Life Sciences Alternatives Verseon Alternatives Scancell Alternatives Ondine Biomedical Alternatives Mereo BioPharma Group plc (MPH.L) Alternatives hVIVO Alternatives Open Orphan Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:SBTX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SkinBioTherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share SkinBioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
